Aura Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, MA – March 5, 2019 – Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that management will present a company overview at the following investor conferences:

  • Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 10:00 a.m. Eastern Time in Boston, MA

  • Oppenheimer's 29th Annual Healthcare Conference on Tuesday, March 19, 2019, at 9:10 a.m. Eastern Time in New York, NY

About Aura Biosciences

Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 in primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit www.aurabiosciences.com

Contacts:

Media:

David Rosen

Argot Partners

212.600.1902 | david.rosen@argotpartners.com

 

Investors:

Joseph Rayne

Argot Partners

617.340.6075 | joseph@argotpartners.com 

Written by:

Comment on this blog post by clicking the Post Comment button below, clicking the icon, and entering your name and email address. Any comments submitted without both a name and email address will not be approved to post publicly. For more information, read Aura’s blog guidelines here.